- Home
- RCUS vs ETY Comparison
RCUS vs ETY Comparison
Compare RCUS & ETY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCUS | ETY |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | RCUS | ETY |
|---|---|---|
| Price | $23.08 | $15.17 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $28.89 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 247.3K |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.21% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $240,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.50 | $10.59 |
| 52 Week High | $26.40 | $13.46 |
Technical Indicators
Market Signals| Indicator | RCUS | ETY |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 42.31 |
| Support Level | $20.70 | $14.95 |
| Resistance Level | $23.40 | $15.60 |
| Average True Range (ATR) | 1.44 | 0.17 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 61.75 | 29.60 |
Price Performance
Historical ComparisonAbout RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.